Vous n'êtes pas connecté
THURSDAY, Jan. 23, 2025 -- Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk for stroke, according...